3-pyr-Cytisine
目录号 : GC10484
α4β2 receptors agonist
Cas No.:948027-43-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
3-pyr-Cytisine is a partial agonist of α4β2 receptor with Ki values of 0.91, 119 and 1100 nM for α4β2, α3β4 and α7 receptors, respectively [1].
The alpha-4 beta-2 nicotinic receptor (α4β2 receptor) is a nicotinic acetylcholine receptor participated in learning and is widely expressed in the central nervous system. Also, α4β2 receptor has the highest affinity for nicotine.
3-pyr-Cytisine is an α4β2 receptor partial agonist. In cells expressed α4β2 receptor, 3-pyr-Cyt reduced the agonist response by ACh, which relayed on the intrinsic activity of 3-pyr-Cyt and 3-pyr-Cyt concentration [1]. In PC12 cells, 3-pyr-Cyt significantly induced release of norepinephrine (NE) in a time-, dose- and Ca2+-dependent way. Also, 3-pyr-Cyt inhibited nicotine-induced NE release and increased the mRNA levels of tyrosine hydroxylase (TH), which is necessary for catecholamine biosynthetic [2].
In the tail suspension test, mice treated with 3-pyr-Cyt (0.6 mg/kg) spent significantly less time immobile in a dose-dependent way. In the forced swim test, mice treated with 3-pyr-Cyt (0.3, 0.6 or 0.9 mg/kg) were significantly less immobile in a dose-dependent way, which suggested that 3-pyr-Cyt exhibited antidepressant-like effects in a dose-dependent way [1].
References:
[1]. Mineur YS, Eibl C, Young G, et al. Cytisine-based nicotinic partial agonists as novel antidepressant compounds. J Pharmacol Exp Ther, 2009, 329(1): 377-386.
[2]. Turcanu DS, Kirtok N, Eibl C, et al. Nicotinic receptor partial agonists alter catecholamine homeostasis and response to nicotine in PC12 cells. Neurosci Lett, 2012, 516(2): 212-216.
| Cas No. | 948027-43-8 | SDF | |
| 化学名 | (1R,5S)-9-(pyridin-3-yl)-3,4,5,6-tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one | ||
| Canonical SMILES | O=C1C(C2=CN=CC=C2)=CC=C3[C@]4([H])C[C@@](CN31)([H])CNC4 | ||
| 分子式 | C16H17N3O | 分子量 | 267.33 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7407 mL | 18.7035 mL | 37.407 mL |
| 5 mM | 0.7481 mL | 3.7407 mL | 7.4814 mL |
| 10 mM | 0.3741 mL | 1.8703 mL | 3.7407 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。